• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Pro-Dex Inc.

    5/30/24 4:00:03 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care
    Get the next $PDEX alert in real time by email
    SD 1 pdex_sd.htm FORM SD

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

    Form SD

     

    SPECIALIZED DISCLOSURE REPORT

     

    Pro-Dex, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

    COLORADO   000-14942   84-1261240

    (State or Other Jurisdiction of Incorporation

    or Organization)

      (Commission File Number)   (IRS Employer Identification Number)

     

     
     

    2361 McGaw Avenue,

    Irvine, California

      92614
      (Address of Principal Executive Offices)   (Zip Code)

      

    Alisha K. Charlton   (949)769-3231
     (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

    ☒Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2023.

     


     
     

    Section 1 - Conflict Minerals Disclosure

     

    Item 1.01 and 1.02 Conflict Minerals Disclosure and Report, Exhibit

     

    A copy of Pro-Dex, Inc.’s (“Company,” “Pro-Dex,” “we,” “our,” “us”) Conflict Minerals Report for this reporting period January 1, 2023 to December 31, 2023 is provided as Exhibit 1.01 hereto and is publicly available at www.pro-dex.com/investor-relations. Pro-Dex’s determination related to disclosures relating to conflict minerals is included in our Conflict Minerals Report and incorporated by reference herein.

     

    We undertook due diligence measures, including surveying our direct suppliers through an industry-standard survey template for conflict minerals, to try to determine the sources of these minerals, which we purchase through a complex supply chain. Currently, we do not have sufficient information from all our suppliers or other sources to determine the country of origin of the conflict minerals used in our products or to identify the facilities used to process those conflict minerals.

     

    Section 2 - Exhibits

     

    Item 2.01 Exhibits

     

    Exhibit 1.01 - Conflict Minerals Report for the reporting period January 1, 2023 to December 31, 2023

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    Date: May 30, 2024

     

    PRO-DEX, INC.
     
    /s/ Alisha K. Charlton

    Alisha K. Charlton

    Chief Financial Officer


     

     

     

    Get the next $PDEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PDEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PDEX
    SEC Filings

    View All

    Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    1/29/26 4:03:40 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Pro-Dex Inc.

    10-Q - PRO DEX INC (0000788920) (Filer)

    1/29/26 4:00:53 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    12/19/25 4:00:23 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Domingo Angelita Rebamontan was granted 18 shares, increasing direct ownership by 0.12% to 15,465 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    1/23/26 4:00:05 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Director Philp Katrina Marie Kramer was granted 3,100 shares, increasing direct ownership by 45% to 2,900 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/24/25 4:00:02 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Van Kirk Richard Lee Jr covered exercise/tax liability with 72 shares, decreasing direct ownership by 0.07% to 99,707 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/21/25 6:46:37 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

    IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

    10/31/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Third Quarter And Nine-Month Results

    IRVINE, CA / ACCESSWIRE / May 2, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2024 with the Securities and Exchange Commission today.Quarter Ended March 31, 2024Net sales for the three months ended March 31, 2024, increased $1.2 million, or 9%, to $14.3 million from $13.1 million for the three months ended March 31, 2023, due primarily to an increase in medical device product revenue of $2.8 million offset by a decrease in non-recurring engineering and repair revenue of $736,000 and $635,000 respectively.Gross profit for

    5/2/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Financials

    Live finance-specific insights

    View All

    PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

    IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

    10/31/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 First Quarter Results

    IRVINE, CA / ACCESSWIRE / November 2, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 first quarter ended September 30, 2023. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2024 with the Securities and Exchange Commission today.Net sales for the three months ended September 30, 2023, increased $851,000, or 8%, to $11.9 million from $11.1 million for the three months ended September 30, 2022. The increase is driven primarily by $1.8 million in increased repairs of the surgical handpiece we sell to our largest customer offset primarily by a decrease of $0.7 million in sales of our NRE & proto-type offerings

    11/2/23 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Pro-Dex Inc.

    SC 13D - PRO DEX INC (0000788920) (Filed by)

    10/17/23 5:00:05 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed

    SC 13D/A - PRO DEX INC (0000788920) (Subject)

    2/22/21 4:47:58 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care